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Thomas StecklerThe inability to reproduce published findings has been
identified as a major issue in science. Reports of only a
low percentage of landmark studies being reproduced at
pharmaceutical companies like Bayer (Prinz et al. 2011)
gained much interest in the scientific community and
raised high levels of concerns. A more recent analysis
from Amgen (Begley and Ellis 2012) suggested that those
non-reproducible studies may have an even stronger im-
pact on the field than those that can be reproduced, pos-
sibly because the more remarkable and exciting findings
are reported in higher impact journals. Evidently, this is
not just a problem of pharmaceutical industry. About
half of respondents from faculty and trainees at the aca-
demic MD Anderson Cancer Center, Houston, Texas,
had experienced at least one episode of inability to re-
produce published data in a survey by Mobley et al.
(2013) and comparable figures may be expected in
neuroscience.
Why worry?
Insufficient data reproducibility and integrity is a major
concern, not only from a pure scientific perspective, but
also because of potentially serious financial, legal and
ethical consequences. It is currently estimated that up to
85% of resources are wasted in science (Chalmers and
Glasziou 2009; Macleod et al. 2014). Investigational costs
for a single case of misconduct may be in the range of
US$ 525,000, amounting to annual costs exceeding US$
100 MM for the US alone (Michalek et al. 2010). Such
figures clearly contribute to a genuine dissatisfaction
about the situation, also in the public domain, where
questions on whether government spending on biomed-
ical research is still justified are raised (The Economist
2013). In response, bodies like the Wellcome Trust or
the Science Foundation Ireland implemented formal
audit processes to combat misconduct and misuse of
taxpayer’s money (Van Noorden 2014; Wellcome Trust
2013) and some research institutions where employeesCorrespondence: tsteckle@its.jnj.com
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in any medium, provided the original work is pwere directly involved in misconduct took drastic steps,
including major re-organizations that affected large pro-
portions of its staff (Normile 2014). Consequently, more
transparency in reporting of preclinical data has been re-
quested and best practices in experimental design and
reporting proposed (Ioannidis 2014; Landis et al. 2012) -
and in fact are urgently required!
The magnitude of the problem is further illustrated by
a steep rise of retracted publications over the last years,
with a high percentage suggested to be due to miscon-
duct (fabrication and falsification, plagiarism or self-
plagiarism) and more than 10% to be due to irreprodu-
cible data (Van Noorden 2011). The issue is not limited
to published studies, although here the impact on the
wider scientific community is possibly most severe.
Problems were also observed in contract labs working
for the pharmaceutical industry (Nature Medicine Opin-
ions 2013; Selyukh and Yukhananov 2011) and industry
itself is not without fault (e.g., Cyranoski 2013). The po-
tential consequences for pharmaceutical industry are
major and may lead from delays in drug development to
potential retraction of drugs from the market, let alone
the potential risks to human volunteers and patients.
This issue of reproducibility is highlighted against a
background of increasing globalization of science and
outsourcing activities from the pharmaceutical industry,
with estimates that more than 30% of the annual busi-
ness expenditure of pharma R&D in the US is spent on
external research (Moris and Shackelford 2014) and pro-
jections that the global preclinical outsourcing market is
still expanding, possibly more than doubling in growth
from 2009 to 2016 (Mehta 2011). Whilst there are many
advantages to externalize research, it also means people
have to rely more on data generated by third parties that
themselves may feel obliged to deliver what they think is
expected by their customers. Furthermore, dealing with
data from an external source adds an additional level of
complexity to the already complex issue of data quality
assurance. Conversely, in academia there is increasing
pressure to deliver publications in order to be successfulpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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ment) or, one may argue, to be an interesting partner for
industry.
What are the issues at hand?
Partly driven by the situation of dwindling funding,
many investigators are attracted to work in emerging
and ‘hot’, but also very complex and competitive fields of
science and like to use the most recent technology and in-
novative experimental designs. By taking this interesting
approach, which may yield a lot of novel insights, there is
a greater likelihood of receiving more favourable reviews
of grant applications as well, especially as many grant
schemes emphasize innovation rather than other aspects,
such as reproducibility. Moreover, studies may get more
rapidly published, often in so-called high impact journals,
even if rather small and underpowered and, in this con-
text, it may be more acceptable that reported effect
sizes are small. However, all these factors diminish the
positive predictive value of a study, i.e., the likelihood
that results are true positives (Button et al. 2013; Ioan-
nidis 2005). This issue is by no means limited to preclin-
ical work or in vivo behavioural studies. It is also a
concern for biomarker studies that play pivotal roles in
drug discovery (Anderson and Kodukula 2014) and the
many small explorative, clinical proof-of-concept studies
often used to come to go/no-go decisions on drug devel-
opment programs.
Often there is also an uncritical belief in p-values;
over-reliance on highly significant, but also variable,
p-values has been considered to be another important
factor contributing to the high incidence of non-
replication (Lazzeroni et al. 2014; Motulsky 2014; Nuzzo
2014). In general it is believed that expert statistical input
is currently under-utilized and can help address issues of
robustness and quality in preclinical research (Peers et al.
2012; 2014).
This ‘publish or perish’ pressure may also lead investi-
gators to neglect findings, not conform to their hypoth-
esis and instead to go for the desired outcome, may bias
authors to publish positive, statistically significant results
(Tsilidis et al. 2013) and to abandon negative results that
they believe journals are unlikely to publish (the file-
drawer phenomenon; Franco et al. 2014). This pressure
to publish may even entice investigators to make post-
hoc alterations to hypotheses, data, or statistics (Motulsky
2014; O’Boyle et al. 2014), so that there is a more compel-
ling story to tell, essentially transforming uninteresting re-
sults into top-notch science (the chrysalis effect; O’Boyle
et al. 2014). Reviewers of these manuscripts are also not
free of bias, being possibly more willing to accept data that
conform to their own scientific concepts; editors have an
appetite for positive and novel findings rather than nega-
tive or ‘incremental’ results, and journals compete topublish breakthrough findings to boost their impact factor,
which is calculated within the first two years of publica-
tion, whereas the n-year impact factor and the citation
half-life receive considerably less attention. All of this,
paired with the ease of publication in a world of electronic
submissions and re-submissions with short turnaround
times, generates a self-fulfilling, vicious circle. Unfortu-
nately, there is no greater widely accepted forum where
replication studies or negative studies can be published,
although those data inevitably exist and are of equal im-
portance to the field, let alone the ethical principles con-
cerning repeated use of animals to show something does
not work because publication of negative findings is
discouraged.
Attempts to reproduce published findings are further
hampered as many publications simply lack the detailed
information required to reproduce experiments (Kilkenny
et al. 2009). Indeed a recent analysis concluded that less
than half of the neuroscience publications included in that
analysis reported sufficient methodological detail to unani-
mously identify all materials/resources (Vasilevsky et al.
2013). Detailed information, however, is essential, espe-
cially in areas where tests and assays are not standardized
and where there is high variability in experimental design
and methodological detail across studies. This is fre-
quently evident across many in vivo pharmacological re-
ports (e.g., using different strains of rats or mice, sources
of animals, housing conditions, size and made of test ap-
paratus, habituation and training procedures, vehicles for
drugs; e.g., Wahlsten 2001; Wahlsten et al. 2003), but
in vitro studies may not fare much better either. Conse-
quently, journals publishing original work must adhere to
a minimum set of standards to even allow replication
studies to be conducted, and many journals and editors
have taken action to improve the information content
provided in publications (McNutt 2014; Nature Editorial
2014), for example, by providing checklists that prompt
authors to disclose important methodological details
(Nature Editorial 2013).
The inability to reproduce due to lack of detailed in-
formation would possibly be less of an issue if data were
robust. A robust finding should be detectable under a
variety of experimental conditions, making obsolete the
requirement for exact, point-by-point reproduction. It
could possibly even be argued that most replication
studies are in fact studies testing the robustness of
reported findings, since it may be difficult to exactly re-
capitulate all details and conditions under which the ori-
ginal data were produced. Moreover, robust data could
be considered more important as they can be seen under
varying conditions and may be biologically more rele-
vant. On the other hand, claims of non-reproducibility
which do not utilise information that is provided in the
original publication should also be carefully scrutinized
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the case. This in turn implies that we should not only
encourage publication of reproduction attempts but also
allow publications investigating the robustness of a re-
ported effect and the validity of attempted replications.
While replication studies are usually performed by in-
dependent labs, replication attempts can of course also
take place within the same laboratory, assessing the de-
gree to which a test or assay produces stable and con-
sistent results across experiments (intra-lab reliability). If
intra-lab reliability is already low it comes as no surprise
that reproducibility across labs (inter-lab reliability) is
low as well, if not worse. Therefore, not only inter-lab
replication studies, but also reports of attempts to sys-
tematically evaluate the intra-lab reliability of a particu-
lar test provide important information and publication
of such data should be encouraged.
Particularly impacting the media, especially via the so-
cial media, are cases of fraud. Fraud or suspected fraud
has been suggested to account for more than 40% of
retracted papers in the biomedical sciences and life sci-
ences (Fang et al. 2012), which is extremely alarming, al-
though it is important to be reminded that the number
of retracted articles is low compared to the huge number
of articles that get published each year. However, a
meta-analysis and systematic review of survey data con-
cluded that close to 2% of scientists admitted to have
fabricated, falsified or modified data or results at least
once (Fanelli 2009). But contrary to fraudulent articles
that are retracted upon detection of the misconduct,
non-reproducible results hardly ever get retracted and
yet may influence the field for years.
What are the implications for neuroscience?
Because scientific advance is iterative, non-reproducibility,
low reliability, lack of robustness and false discoveries have
major implications, which go well beyond the waste of the
taxpayer’s money. Researchers may waste their time and
efforts, being misled by wrong assumptions, and that way
may even jeopardize their future careers, but even more
important is the loss of time for patients waiting for new
therapies. Misguided research may lead to misdiagnosis,
mistreatment and ill-advised development of new thera-
peutic approaches that lack efficacy and/or suffer from un-
acceptable side effects.
If negative data and failures to reproduce published
work remain unshared, it essentially means that very
valuable information for the field is withheld, potentially
resulting in duplication of efforts, from which ethical
questions arise, since in principle it contradicts one of
the goals of the 3R’s (i.e., reduction) in animal research.
Moreover, preclinical efficacy data are increasingly con-
sidered unreliable and being of low quality, especially be-
havioural data which, in many cases mistakenly, areconsidered nice-to-have rather than obligatory. Given
the already very complex nature of neuroscientific re-
search, with high demand for more effective therapies,
coupled to low success rates to develop such therapies
and high development costs (Frantz 2004; Kola and
Landis 2004), there is disappointment in the lack of pre-
dictability and reliability of those data. As such there is an
unwillingness to invest further in these areas and it may
be speculated that this situation contributed, at least in
part, to decisions of major pharmaceutical companies to
exit the neuroscience field.
Can we resolve the situation?
Recognizing this situation, a number of organizations
have started to take action, including pharmaceutical
companies, academia, governmental bodies, charities,
editors and publishers (e.g., Landis et al. 2012; McNutt
2014; Nature Editorial 2014) and some scientists even
took the initiative to replicate studies of critical data by
independent labs prior to publication (Schooler 2014).
These are important steps towards improved data re-
producibility. However, it is also very relevant to share
the outcome of those activities more widely amongst sci-
entists. While there are more instances now where ef-
forts to reproduce published data can be shared with the
scientific community (cf. some recent attempts to repro-
duce some findings reported with the drug bexarotene;
Fitz et al. 2013; Price et al. 2013; Tesseur et al. 2013),
those publications are still more an exception than the
norm, yet provide very valuable information to the field.
Fortunately, this is increasingly recognized and a num-
ber of programs have recently been launched to make it
easier to publish studies aiming at reproducibility. One
of these initiatives is a new Springer platform, focusing
on publications of peer-reviewed studies concerned with
reproduction of recently reported findings in the neuro-
science area. This section, which is called “Replication
Studies in Neuroscience”, is part of the open access,
electronic SpringerPlus journal (http://www.springerplus.
com/about/update/RepStudNeuro). Neuroscientists, in-
cluding the readers of Psychopharmacology, should feel
encouraged to submit replication studies to journals like
this. Sharing these results is highly relevant to Psycho-
pharmacology, both to the research field and to the jour-
nal, as it hopefully will help to increase the positive
predictive value of our tests and assays, will contribute to
scientific quality and eventually help to re-build trust in
research and neuroscience in general.
Although this article makes a plea for greater emphasis
on reproducibility, there should also not be a shift to an
aggressively sceptical tendency where some scientists
make their names by failing to repeat others’ work or
where careers of brilliant young scientists are jeopar-
dized because someone else published an article failing
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timidatory and threatening situation for many excellent
scientists working in good faith to produce robust and
useful data. The quest for reproducibility needs to be
conducted in a scientific and ethical manner which pays
careful attention to its consequences. But what is needed
is a cultural change that puts more emphasis on the
value of data reproducibility, reliability and robustness of
data, rather than just novelty aspects. We hope initia-
tives like the ones mentioned above can make a contri-
bution to this endeavour.
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